MarketLens
Sign Up

What's Driving Exelixis' Recent Momentum and 2026 Outlook

6 months ago
SHARE THIS ON:

What's Driving Exelixis' Recent Momentum and 2026 Outlook

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 weeks ago

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Exelixis (EXEL) is positioned to beat earnings estimates in its next quarterly report, based on its impressive earnings surprise history and a favorable combination of key ingredients.
Stock News•2 months ago

Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data

Exelixis was downgraded to Hold after cutting FY2026 revenue guidance to $2.500–$2.550B, despite Q2 revenues rising to $628.7M. Zanzalintinib plus TECENTRIQ showed overall survival benefit in mCRC but...
Stock News•3 months ago

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

Krystal Biotech and Exelixis have outperformed the market this year, driven by strong sales in underserved therapeutic areas and a niche in the cancer-drug market.

Breaking News

View All →

Top Headlines

View More →
Stock News•43 minutes ago

Apple posts record September quarter under new CEO as iPhone, Mac sales surge

Stock News•55 minutes ago

Alphabet Lost $500 Billion in Market Value. Should You Really Buy AI Stocks Now?

Stock News•59 minutes ago

Apple Q4: Another Solid Result

Stock News•59 minutes ago

Molly Pieroni Names GOOGL & MSFT Strong Investments in "Topsy-Turvy" Market

Stock News•1 hour ago

Apple Looks Very Smart in Modest AI Spend: Tom Forte